For instance, pre-clinical trials already showed that stimulating TRPC5 with riluzole could represent a promising strategy to treat PAD, while the intra-myocardial/coronary injection of P3HT nanoparticles coupled to optical pacing of the heart could stimulate circulating ECFCs to rescue coronary circulation upon TRPV1 activation. Here, TRPV1 is linked to peripheral arterial disease.